ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 259 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $15,230 | -91.6% | 586 | -90.2% | 0.00% | – |
| Q4 2023 | $182,376 | +69.2% | 5,960 | +48.6% | 0.00% | – |
| Q3 2023 | $107,776 | -77.9% | 4,011 | -70.7% | 0.00% | -100.0% |
| Q2 2023 | $488,578 | +151.2% | 13,701 | +78.9% | 0.00% | +100.0% |
| Q1 2023 | $194,513 | -87.3% | 7,658 | -79.7% | 0.00% | -75.0% |
| Q4 2022 | $1,531,464 | +107.8% | 37,758 | +69.3% | 0.00% | +300.0% |
| Q3 2022 | $737,000 | +19.8% | 22,309 | +27.7% | 0.00% | 0.0% |
| Q2 2022 | $615,000 | -30.8% | 17,475 | -9.6% | 0.00% | 0.0% |
| Q1 2022 | $889,000 | -82.5% | 19,337 | -74.8% | 0.00% | -75.0% |
| Q4 2021 | $5,091,000 | +6.8% | 76,780 | +0.5% | 0.00% | -20.0% |
| Q3 2021 | $4,768,000 | -11.5% | 76,380 | +17.5% | 0.01% | -16.7% |
| Q2 2021 | $5,385,000 | +20.6% | 65,025 | -3.5% | 0.01% | -14.3% |
| Q1 2021 | $4,467,000 | +57.6% | 67,366 | +82.3% | 0.01% | +40.0% |
| Q4 2020 | $2,835,000 | -11.2% | 36,950 | -50.1% | 0.01% | -50.0% |
| Q3 2020 | $3,191,000 | +206.8% | 74,104 | +207.9% | 0.01% | +100.0% |
| Q2 2020 | $1,040,000 | -58.1% | 24,071 | -72.1% | 0.01% | -75.0% |
| Q1 2020 | $2,484,000 | +65.0% | 86,349 | +264.0% | 0.02% | +100.0% |
| Q4 2019 | $1,505,000 | +180.8% | 23,722 | +24.8% | 0.01% | +150.0% |
| Q3 2019 | $536,000 | +16.8% | 19,015 | -24.0% | 0.00% | -20.0% |
| Q1 2019 | $459,000 | -2.5% | 25,007 | -34.0% | 0.01% | +25.0% |
| Q4 2018 | $471,000 | +344.3% | 37,916 | +386.5% | 0.00% | +300.0% |
| Q2 2018 | $106,000 | -78.6% | 7,793 | -88.7% | 0.00% | -80.0% |
| Q1 2018 | $496,000 | +190.1% | 68,738 | -34.9% | 0.01% | +150.0% |
| Q2 2017 | $171,000 | -16.6% | 105,588 | -4.8% | 0.00% | 0.0% |
| Q1 2017 | $205,000 | -6.8% | 110,888 | -21.8% | 0.00% | 0.0% |
| Q4 2016 | $220,000 | -50.0% | 141,860 | +137.1% | 0.00% | -60.0% |
| Q3 2016 | $440,000 | +4788.9% | 59,832 | +3497.8% | 0.01% | – |
| Q2 2016 | $9,000 | – | 1,663 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $206,837,000 | 74.59% |
| ACUTA CAPITAL PARTNERS, LLC | 442,500 | $28,068,000 | 6.95% |
| Vanguard Capital Wealth Advisors | 19,884 | $1,261,000 | 1.32% |
| Matarin Capital Management, LLC | 193,171 | $12,253,000 | 1.17% |
| Ikarian Capital, LLC | 100,000 | $6,343,000 | 1.03% |
| Ikarian Capital, LLC | 100,000 | $6,343,000 | 1.03% |
| HRT FINANCIAL LP | 299,297 | $18,984,000 | 0.82% |
| EAM Investors, LLC | 50,411 | $3,198,000 | 0.70% |
| OAK RIDGE INVESTMENTS LLC | 147,293 | $9,343,000 | 0.69% |
| FIRST MANHATTAN CO. LLC. | 2,068,020 | $131,174,000 | 0.66% |